Published in Proc Natl Acad Sci U S A on April 26, 2010
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog (2014) 1.88
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A (2014) 1.54
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer (2013) 0.96
Liver regeneration signature in hepatitis B virus (HBV)-associated acute liver failure identified by gene expression profiling. PLoS One (2012) 0.91
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics (2015) 0.89
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure. J Struct Biol (2012) 0.89
Epitope-distal effects accompany the binding of two distinct antibodies to hepatitis B virus capsids. J Am Chem Soc (2013) 0.86
Immunopathogenesis of chronic hepatitis B. World J Gastroenterol (2014) 0.84
Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World J Hepatol (2015) 0.83
Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Braz J Med Biol Res (2012) 0.80
Two sides of one coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure. Front Physiol (2015) 0.80
Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J Transl Med (2014) 0.80
Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation. Sci Rep (2016) 0.78
Integrated ordination of miRNA and mRNA expression profiles. BMC Genomics (2015) 0.77
Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. Sci Rep (2016) 0.77
Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue. Arch Toxicol (2016) 0.75
Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure. Biomed Res Int (2016) 0.75
Changes in gene expression in liver tissue from patients with fulminant hepatitis E. World J Gastroenterol (2015) 0.75
Liver Failure due to Acute Viral Hepatitis (A-E). Visc Med (2016) 0.75
On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol (2016) 0.75
S-phase arrest after vincristine treatment may promote hepatitis B virus replication. World J Gastroenterol (2015) 0.75
The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center. Bone Marrow Transplant (2016) 0.75
Immune mediated liver failure. EXCLI J (2014) 0.75
High-throughput sequencing of the zebrafish antibody repertoire. Science (2009) 4.46
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Acute liver failure. N Engl J Med (1993) 3.81
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
A molecular perspective of CTLA-4 function. Annu Rev Immunol (2006) 2.71
The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science (1986) 2.71
A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med (1991) 2.68
B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol (2006) 2.49
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology (1987) 2.02
Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance. Gut (1976) 1.74
Acute liver failure in Spain: analysis of 267 cases. Liver Transpl (2007) 1.71
Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol (2004) 1.68
Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med (1995) 1.63
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol (2007) 1.49
Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut (1980) 1.29
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat (2005) 1.19
Serological markers in fulminant hepatitis B. Gut (1983) 1.15
Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling. J Exp Med (2000) 1.11
Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol (2006) 1.09
Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J (2008) 1.02
Antiviral antibody-producing cells in parenchymatous organs during persistent virus infection. J Exp Med (1987) 0.96
Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol (2006) 0.90
Evidence for phasic sequences in nuclear HBcAg formation and cell membrane-directed flow of core particles in chronic hepatitis B. Gastroenterology (1977) 0.90
Hepatitis B virus mutants. Intervirology (1999) 0.89
Aetiology and outcome of acute hepatic failure in Greece: experience of two academic hospital centres. Liver Int (2008) 0.86
Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunol (2008) 0.85
C4d: a marker for hepatic transplant rejection. Transplant Proc (2006) 0.85
Immune response in fulminant viral hepatitis, type B. Gastroenterology (1976) 0.83
Fulminant viral hepatitis. Br Med Bull (1990) 0.82
Electron microscopic study of hepatitis B virus-associated antigens on the infected liver cell membrane in relation to analysis of immune target antigens in chronic hepatitis B. Gastroenterol Jpn (1992) 0.79
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics (2006) 4.52
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood (2011) 4.21
A paradigm for class prediction using gene expression profiles. J Comput Biol (2002) 3.64
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A (2002) 3.43
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Hepatitis E virus. Rev Med Virol (2003) 3.34
Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics (2002) 3.31
Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog (2010) 3.28
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res (2005) 3.02
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 2.77
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst (2007) 2.68
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics (2010) 2.52
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell (2008) 2.46
Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood (2002) 2.43
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol (2004) 2.30
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood (2002) 2.28
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol (2010) 2.22
Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant (2004) 2.22
Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev (2003) 2.22
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst (2010) 2.16
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood (2008) 2.15
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer (2004) 2.13
The cross-validated adaptive signature design. Clin Cancer Res (2010) 2.12
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 2.07
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science (2013) 2.00
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Hepatitis E. N Engl J Med (2012) 1.99
Evaluation of normalization methods for microarray data. BMC Bioinformatics (2003) 1.97
Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A (2010) 1.96
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A (2003) 1.93
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Evaluation of randomized discontinuation design. J Clin Oncol (2005) 1.89
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood (2014) 1.88
NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood (2010) 1.83
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A (2011) 1.81
Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood (2011) 1.81
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood (2006) 1.78
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol (2005) 1.77
Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis (2008) 1.75
Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics (2005) 1.72